Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Income: 2013-2025

Historic Operating Income for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $25.3 million.

  • Amphastar Pharmaceuticals' Operating Income fell 55.62% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 30.02%. This contributed to the annual value of $205.4 million for FY2024, which is 4.28% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Operating Income of $25.3 million as of Q3 2025, which was down 39.98% from $42.2 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Operating Income peaked at $72.7 million during Q3 2023, and registered a low of $10.3 million during Q1 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Operating Income averaged around $46.1 million, with its median value being $45.1 million (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Operating Income spiked by 742.38% in 2021 and then tumbled by 55.62% in 2025.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Operating Income stood at $24.3 million in 2021, then surged by 56.00% to $37.8 million in 2022, then spiked by 42.68% to $54.0 million in 2023, then dropped by 16.37% to $45.1 million in 2024, then crashed by 55.62% to $25.3 million in 2025.
  • Its Operating Income stands at $25.3 million for Q3 2025, versus $42.2 million for Q2 2025 and $37.3 million for Q1 2025.